The objectives of this study were (1) t o determine the clinical presentation and natural history associated with t w o newly recognized pathologic entities termed mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL), including the mucosa-associated lymphoid tissue (MALT) and monocytoid B-cell subcategories, and (2) t o determine whether these entities differ clinically from the other relatively indolent non-Hodgkin's lymphomas with which they have been previously classified. We reviewed the conventional pathology and clinical course of 376 patients who had no prior therapy; had stage III/IV disease; were classified as Working Formulation categories A, B, C, D, or E; and received cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) on Southwest Oncology Group (SWOG) studies no. .7204, 7426, or 7713. All slides were reviewed by the three pathologists who reached a consensus diagnosis. Age, sex, performance status, bone marrow and/or gastrointestinal involvement, failure-free survival, and overall survival were ORE THAN 10 YEARS have elapsed since the publication of the National Cancer Institute's Working Formulation (WF) that provided a common language for translating between the Rappaport, Lukes-Collins, Kiel, and World Health Organization lymphoma classification schemes.' In the intervening years, several new pathologic entities have been recognized using morphologic, immunologic, and genetic methods. These new entities are not easily categorized in the existing classification schemes. Furthermore, the clinical behavior of these new entities has been generally described only at single institutions in small series of patients who have been treated with a variety of therapeutic approaches.
ORE THAN 10 YEARS have elapsed since the publication of the National Cancer Institute's Working Formulation (WF) that provided a common language for translating between the Rappaport, Lukes-Collins, Kiel, and World Health Organization lymphoma classification schemes.' In the intervening years, several new pathologic entities have been recognized using morphologic, immunologic, and genetic methods. These new entities are not easily categorized in the existing classification schemes. Furthermore, the clinical behavior of these new entities has been generally described only at single institutions in small series of patients who have been treated with a variety of therapeutic approaches.
Among these new entities are cases of lymphoma that have been classified as lymphocytic lymphoma of intermediate differentiation, intermediate lymphocytic lymphoma, centrocytic lymphoma, or mantle zone lymphoma.'-' The term "mantle cell lymphoma" (MCL) has been recently proposed to replace these terms6 and will be used throughout this report. Lymphomas of mantle cell type have a characteristic morphologic appearance with both distinctive microanatomic and cytologic feature^.^.^ Specifically, MCL is comprised of small lymphoid cells with slightly irregular nuclear outlines and without admixed large transformed cells. Initially, MCL grows around residual normal germinal centers, giving an expanded mantle zone pattern. This zonal or "nodular" pattern progresses to a diffuse effacing pattern. The MCL phenotype is also characterized by expression of Pan B antigens (CD20', CD22+), monotypic Ig (IgM' D') and coexpression of the Pan T antigen CD5.'" MCL also has a characteristic chromosomal translocation t( 11; 14) involving the Ig heavy chain locus and the bcl-l oncogene that results in the overexpression of a gene known as PRADI, which encodes for cyclin Dl.'0" 4 A second group of patients have been described as having low-grade B-cell lymphoma of mucosa-associated lymphoid tissue (MALT)"-17 or monocytoid B-cell (MCBC) lym- compared among all the categories. We found that (1) MCL and MZL each represent approximately 10% of stage 111 or IV patients previously classified as Working Formulation categories A through E and treated with CHOP on SWOG clinical trials; (2) the failure-free survival and overall survival of patients with MZL is the same as that of patients with Working Formulation categories A through E, but the failure-free survival and overall survival of the monocytoid B-cell patients were higher than that of the MALT lymphoma patients ( P = .009 and .007, respectively); and (3) the failure-free survival and overall survival of patients with MCL is significantly worse than that of patients with Working Formulation categories A through E ( P = .0002 and .0001, respectively). In conclusion, patients with advanced stage MALT lymphomas may have a more aggressive course than previously recognized. Patients with MCL do not have an indolent lymphoma and are candidates for innovative therapy. phoma.'*-*' The term "marginal zone B-cell lymphoma" (MZL) has been proposed to encompass both of these subcategories and will be used here." The MZL designation derives from a common microanatomic feature; both lymphomas involve the marginal B-cell compartment of lymphoid tissue outside the follicular mantle Both variants also manifest secondary involvement of benign germinal centers described as follicular col~nization.'~ The two entities also show considerable overlap with regard to cellular composition.15-18,21 By definition, MCBC lymphoma is composed chiefly of clear cells with reniform or oval nuclei. MALT lymphoma often includes MCBCs as either a predominant or minority component. The two entities also have a virtually identical immunophenotype." Their common immunophenotype is positive for surface Ig, not of IgD type, positive for B-cell markers CD19, CD20, and CD22 and negative for CD5 and CD23. There is no genetic rearrangement for either bcl-l or bcl-2 loci.22
FISHER ET AL
Although these numerous overlapping morphologic and immunophenotypic features suggest closely related lymphomas, they also have microanatomic and distributional differences reflecting the fact that the extranodal MALT lymphoma is mucosa-based and the MCBC lymphoma is node-based?* In particular, the MALT lymphoma has one specific, defining microanatomic feature, called a lymphoepithelia1 lesion that consists of distinctive lacunae of lymphoma cells within the m u c o~a . '~"~ This clustered trophism for the epithelium of affected extranodal parenchymal is the characteristic MALT lymphoma feature. In contrast, the MCBC lymphoma, which lacks the lymphoepithelioid lesion, has as its defining microanatomic property a lymph node growth pattern of confluent sinuses filled with small lymphoid cells with abundant clear cytoplasm.
These new entities have now been included in the recent "Proposal for an International Consensus on the Classification of Lymphoid Neoplasms."'' To determine the clinical presentation and natural history associated with newly recognized pathologic entities termed MCL and MZL and to determine whether these entities differ clinically from the other indolent lymphomas with which they have been previously classified, we reviewed the pathology and clinical course of 376 previously untreated patients with advanced stage disease and WF categories A, B, C , D, or E, who received cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) on Southwest Oncology Group (SWOG) studies no. 7204, 7426, or 7713. 
PATIENTS AND METHODS

All
Pathologic Review
Each of the new entities in question has a distinctive microanatomic and cytologic definition allowing accurate histologic diagnosis. It is recognized that immunophenotyping, molecular probes, and cytogenetics may be needed to resolve occasional classification issues in these cases. However, for multi-institutional group study purposes, initial morphologic definition for protocol assignment is critical. To this end a morphologic review of historic SWOG low and intermediate grade lymphomas (WF A through E) was initiated.
Two of the authors (P.M.B., T.M.G.) are signatories of the recent "Proposal for an International Consensus on the Classification of Lymphoid Neoplasms,"'* and the third (B.N.N.) is a widely published authority on the subject of MCBC lymphomam as well as on low grade lymphomas in general. Thus, the newly formulated criteria were already familiar to these pathologists and could be applied readily to the microscopic and microanatomic diagnosis of these entities. Consensus morphologic diagnosis was achieved by joint review and agreement on all cases at a multiheaded microscope. The specific morphologic criteria are shown in Figs 1 to 3 and are described below.
MCL
MCL is morphologically homogeneous, being comprised of small, slightly irregular lymphocytes with small nucleoli and scant cytoplasm (Fig 1) . These The histologic growth pattern included both nodular and diffuse tern of nodal effacement. 
MZL
MALT lymphoma. All cases diagnosed as MALT lymphoma involved extranodal sites and all specifically had the distinctive microanatomic features of a lymphoepithelial lesions with several centrocyte-like lymphocytes clustered within epithelial lacunae (Fig  2) .'"'7. 23 In addition, most showed submucosal lymphoma spread around reactive lymphoid follicles to produce a marginal zone pattern, and some showed follicular colonization by centrocyte-like cells.
Cytologically, the lymphoid cells ranged from small round (WF category A) to small cleaved (WF category E) to slightly cleaved (centrocyte-like) cells. Typically, there were degrees of admixed monocytoid cells with slightly lobated (reniform) nuclei with abundant clear cytoplasm. Plasmacytoid differentiation was common. The various cell components were sometimes stratified in the mucosa, giving a multiphasic appearance. '5"7,23 MCBC lymphoma. These lymphomas occurred in a lymph node distribution, the principle criterion for distinction from MALT lymphoma.'"'' The distinctive microanatomic features included an interfollicular marginal zone nodal growth pattern with confluent sinuses (Fig 3) . In some cases, germinal centers were filled with MCBCs, representing a pattern of follicular colonization (Fig 3) .'x-20 The MCBCs are small lymphoid cells with slightly lobated (reniform) nuclei, inapparent nucleoli, and abundant clear cytoplasm. Plasma cells and histiocytes were sometimes admixed. These nodal MCBC lymphomas were distinguished from reactive monocytoid infiltrates primarily by advanced architectural effacement of nodal elements. Other criteria favoring malignancy were cellular pleomorphism, nuclear irregularity, and higher mitotic rate.2" There was a high association of composite lymphoma in MCBC lymphomas, in particular with low grade FL components, suggesting that this lymphoma may evolve with varying morphologic expression."',"
Statistical Methods
Survival time was defined as the time from patient registration to the time of death from any cause. Patients last known to be alive were censored at the date of last contact. Failure-free survival time was measured from registration to progression, relapse, or death from any cause. Survival distributions were estimated using the method reported by Kaplan and Meier.26 Differences in survival between patient groups were analyzed using log-rank tests2' All reported significance tests are two-sided and are not corrected for multiple comparisons. Data analysis is based on follow-up information in the SWOG Statistical Center of June l , 1994; therefore, the median follow-up is 16.5 years. 
RESULTS
Pathologic Categorization
The slides from 376 patients with stage Ill or IV disease who had been previously classified as having WF categories A through E by the SWOG Lymphoma Pathology Committee were reanalyzed by three pathologists (B.N., P.B., and T.G.). The results are shown in Table 1 using both the original Rappaport and WF terminology. A diagnosis of MCL was made in 36 patients (10%). The majority of these patients had been previously categorized as WF category E (diffuse small cleaved cell); the remaining patients were identified in WF A and B categories. No patients were identified in WF C or D. A diagnosis of MZL was made in 43 patients (1 1 %) . These patients were identified in each of the WF categories A through E. As a result of this comprehensive pathology review, 49 additional cases were excluded from WF A through E as well as the MCL and MZL categories. Thus, 248 cases remained in WF A through E.
The 36 patients with MCL could be further subclassified into nodular, diffuse, or blastic variants. The results of that subdivision were are follows: nodular, 14 (39%); diffuse, 10 (28%); and blastic, 12 (33%). The 43 patients with MZL could be further subclassified into MALT, MCBC. and not classifiable variants. The results of that subdivision were as follows: MALT, 19 (44%); MCBC, 21 (49%); and not classifiable, 3 (7%). Thirteen of 21 (62%) patients with MCBC lymphoma had concomitant presence of follicular lymphoma ("composite lymphoma"), whereas 7 of 19 (37%) patients with MALT had composite lymphoma.
Clinical Presentation
The clinical characteristics of the patients with MCL and MZL were compared to the remaining 248 patients in WF categories A through E. The results are shown in Table 2 . Median age of the three groups ranged from 51 to 55 years. There was a male predominance in patients with MCL (81 %) compared with those with MZL (51%) or WF A through E (54%; P = .009). Over 90% of the patients in each group were ambulatory (SWOG performance status [PS] 2). The percentage of patients with bone marrow involvement ranged from 46% to 53%. The percentage of patients with gastrointestinal (GI) involvement was increased in both the mantle cell group (19%) and the marginal zone group (23%) compared with that of the remaining WF A through E patients (4%; P < .001).
As noted previously, the subclassification of the MCLs resulted in three groups of between 10 and 14 patients. Therefore, it is difficult to convincingly separate the clinical characteristics of these subgroups. The blastic subgroup was younger; the diffuse group had fewer males; and the nodular group had the highest percentage with GI involvement. In addition to the fact that the MALT lymphomas were mucosabased and all extranodal, whereas the MCBC lymphomas were node-based, the subclassification of the MZLs into MALT lymphomas and MCBC lymphomas failed to show any significant differences in clinical presentation except that the MALT lymphoma group did have more patients with GI involvement than the MCBC group (8 of 
Failure-Free Survival and Survival
The failure-free survival for the 36 patients with MCL was significantly shorter than that of the 248 remaining patients with WF A through E, as shown in Fig 4A. The 10-year failure-free survival estimate was only 6% compared with 25% for WF A through E ( P = ,0002). The overall 10-year estimated survival, as shown in Fig 4, was also significantly reduced for the MCL patients (8%) as compared with that of the patients with WF A through E (35%; P = .OOOl). In fact, the failure-free survival and overall survival estimates for the patients with MCL were lower than those for WF A, WF B, WF C, WF D, or WF E when examined as separate groups (data not shown).
The subclassification of the MCLs into blastic, diffuse, and nodular did result in statistically different failure-free survival and overall survival curves ( P = .05 for both), as shown in Figs 5A and B, although the biologic significance of these differences is not clear because the 10-year failurefree survival estimates were 0%, lo%, and 7%, respectively.
In contrast, the failure-free survival for the 43 patients with MZL was similar to that of the 248 remaining patients with WF A through E, as shown in Fig 6A. The 10-year failure-free survival estimate was 36% compared with the 25% for WF A through E ( P = .26). The overall 10-year estimated survival, as shown in Fig 6B, was also not significantly reduced for the MZL patients (39%) as compared with that of the patients with WF A through E ( P = .83). Furthermore, if one prefers to compare the failure-free survival and overall survival for the 43 MZL patients with that of the 210 patients in the classically defined low grade lymphomas (WF A, B, and C), the results are also similar ( P = .22 and .89, respectively).
The subclassification of the MZLs into the MALT
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Relapsas IO-Year . . . For personal use only. on October 27, 2017. by guest www.bloodjournal.org From lymphoma and MCBC categories did permit recognition of significant differences in failure-free survival and survival. The 10-year estimated failure-free survival for patients with MALT lymphoma was 21%, compared with 46% for MCBC lymphoma ( P = .009), as shown in Fig 7A. The overall 10-year estimated survival for patients with MALT lymphoma (21%) was significantly reduced compared with that of patients with MCBC lymphoma (53%; P = .007; see Fig 7B) . Although the failure-free survival of MALT lymphoma patients was not significantly reduced as compared with patients with WF A through E ( P = .12), overall survival was reduced ( P = .02; data not shown).
DISCUSSION
During the 1960s and 1970s. there was a proliferation of lymphoma classifications based primarily on morphologic criteria but also incorporating immunologic information on the cell of origin. In 1982, the National Cancer Institutesponsored WF attempted to group pathologic entities based on an analysis of their clinical behavior and also provided a mechanism for translating diagnoses from one classification to another.' Since that time, new pathologic entities have been defined using morphologic, immunologic, and genetic methods. These new entities are not easily categorized in the existing classification schemes. Furthermore, the clinical presentation and natural history of these newly recognized pathologic entities has not been determined in large series of uniformly treated patients to determine whether these entities differ clinically from the other, relatively indolent lymphomas with which they have been previously classified.
The term MCL has now been adopted to refer to patients previously classified as lymphocytic lymphoma of intermediate differentiation, intermediate lymphocytic lymphoma, centrocytic lymphoma, or mantle zone lymphoma.6 These patients have a well-characterized morphologic appearance and distinctive immunologic phenotype (SIgM', IgD+, CDY, CD23-, etc). The expression of CD5 helps distinguish these patients from those with follicular center and MZL. Patients with MCL also have a characteristic t(l1; 14) translocation that results in overexpression of the PRADI gene that encodes for the cyclin D l pr~tein.''"~ Previous clinical studies of these patients had shown a heterogeneous natural history, in that some patients had very aggressive disease whereas others behaved similarly to patients with classic indolent histology? Patients classified as having centrocytic lymphoma in the Kiel classification have an aggressive clinical course. The patients with MCL can be further subclassified into nodular, diffuse, or blastic variants, although the value of this subclassification remains unclear.
In this study, we reviewed the conventional pathology and We also had the advantage of a long follow-up (median, 16.5 years). Based on conventional microscopy alone, that is without the benefit of immunophenotyping, we identified 36 patients (10%) who had been previously characterized as WF A through E as actually having had MCL. The median age, performance status, and percentage of bone marrow involvement were essentially identical to the remaining patients with WF A through E. The median age of patients entered on a clinical trial is probably lower than that of the entire population of patients with these diseases.28 However, there were significant differences between the patients with MCL and W F A through E in the percentage of male patients (81% U 54%) and the percentage with GI involvement (19% V 4%). Furthermore, the failure-free survival and overall survival of patients with MCL was significantly worse than that of patients with WF A through E. At 10 years, 8% of patients with MCL were alive, and only 6% were alive without disease. The corresponding numbers for patients with WF A through E were 25% and 35%. With this uniformly poor prognosis, subclassification of these patients into the nodular, diffuse, or blastic variants seemed to have limited usefulness.
The term MZL has been proposed to include patients with low grade B-cell lymphoma of MALT, MCBC lymphoma, and possibly splenic MZL." These lymphomas express %g+, IgD-, CD19+, CD20+, CD22+, CD5-, and CD23-, and there is no rearrangement of bcl-l or bcZ-2. MALT lymphomas have been characterized by Isaacson and colleagues as frequently presenting with localized extranodal disease involving glandular epithelial tissues, especially the stomach where they have been associated with helicobacter g a s t r i t i~.~~,~~. '~ Reportedly, localized disease could be cured in a high percentage of cases with minimal local Disseminate disease was reported in only 30% of cases, but these patients also could have long disease-free survival. MCBC lymphoma, representing the nodal counterpart of MALT lymphomas:' predictably had an indolent clinical course.
On the basis of conventional microscopic criteria alone, we identified 43 patients (1 1%) with MZL. The median age, sex, performance status, and percentage of bone marrow involvement were essentially identical to the remaining patients with WF A through E. Again, there were significant differences between the patients with MZL and WF A through E in the percentage with GI involvement (23% v 4%). In this case, the failure-free survival and overall survival of patients with MZL were similar to that of the remaining patients with WF A through E (P = .26 and .83, respectively). Subdivision of the patients with MZL into those with MALT lymphoma versus MCBC lymphoma showed, as expected, that the mucosa-based MALT lymphomas all manifest extranodal involvement, whereas the nodebased MCBC lymphomas infrequently manifest extranodal involvement. Otherwise, the two variants were clinically similar except that the MALT lymphoma group had a higher percentage with GI involvement (42%) than did the MCBC group (10%; P = .03). In addition, both the failure-free survival and overall survival of the MCBC patients were higher than that of the MALT lymphoma patients ( P = .W9 and .007, respectively). It is of interest that this group of advanced stage MALT lymphoma patients who were treated with combination chemotherapy had a median failure-free survival of only 2.3 years. This suggests that MALT-type lymphomas, after they disseminate, are not a favorable subcategory of low grade disease.
We found 2 of 21 MCBC lymphomas with extranodal GI involvement. As pointed out by earlier some cases designated MCBC lymphoma on the basis of microscopy of lymph nodes may originally have been MALT-type lymphomas that spread to involve nodes. Alternatively, these might be MCBC lymphomas that secondarily involve the gut. It remains uncertain whether the 2 cases of 21 MCBC lymphoma with GI involvement are secondary, extranodal MCBC or primary MALT-type lymphoma with nodal spread. Nonetheless, when these two cases are excluded from survival analysis, MCBC of nodal type remains separable from extranodal MALT lymphomas with regard to survival and time to relapse.
In summary, patients with advanced stage MZL have a clinical course similar to that of other patients in WF A through E, although patients with advanced stage MALT lymphomas may have a more aggressive course than previously recognized. However, patients with MCL do not have an indolent lymphoma and are candidates for innovative therapy.
